The price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed at $115.21 in the last session, down -1.46% from day before closing price of $116.92. In other words, the price has decreased by -$1.71 from its previous closing price. On the day, 512011 shares were traded. JAZZ stock price reached its highest trading level at $118.01 during the session, while it also had its lowest trading level at $115.10.
Ratios:
We take a closer look at JAZZ’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.73. For the most recent quarter (mrq), Quick Ratio is recorded 1.74 and its Current Ratio is at 2.12. In the meantime, Its Debt-to-Equity ratio is 1.55 whereas as Long-Term Debt/Eq ratio is at 1.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on January 03, 2024, initiated with a Outperform rating and assigned the stock a target price of $160.
On November 27, 2023, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $170 to $135.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 07 ’24 when Carr Patricia sold 1,768 shares for $116.98 per share. The transaction valued at 206,821 led to the insider holds 6,596 shares of the business.
Carr Patricia sold 1,936 shares of JAZZ for $231,628 on Mar 06 ’24. The SVP, Chief Accounting Officer now owns 8,364 shares after completing the transaction at $119.64 per share. On Mar 01 ’24, another insider, Johnson Philip L, who serves as the EVP & Chief Financial Officer of the company, bought 12,000 shares for $119.65 each. As a result, the insider paid 1,435,800 and bolstered with 27,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 7.18B and an Enterprise Value of 11.34B. As of this moment, Jazz’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.96, and their Forward P/E ratio for the next fiscal year is 5.48. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.87 while its Price-to-Book (P/B) ratio in mrq is 1.92. Its current Enterprise Value per Revenue stands at 2.96 whereas that against EBITDA is 9.25.
Stock Price History:
Over the past 52 weeks, JAZZ has reached a high of $147.98, while it has fallen to a 52-week low of $111.25. The 50-Day Moving Average of the stock is 122.50, while the 200-Day Moving Average is calculated to be 126.69.
Shares Statistics:
According to the various share statistics, JAZZ traded on average about 621.62K shares per day over the past 3-months and 657.63k shares per day over the past 10 days. A total of 62.26M shares are outstanding, with a floating share count of 60.28M. Insiders hold about 3.31% of the company’s shares, while institutions hold 92.82% stake in the company. Shares short for JAZZ as of Mar 15, 2024 were 2.77M with a Short Ratio of 4.45, compared to 2.32M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.44% and a Short% of Float of 5.12%.
Earnings Estimates
The company has 16 analysts who recommend its stock at the moment. On average, analysts expect EPS of $4.2 for the current quarter, with a high estimate of $4.7 and a low estimate of $3.73, while EPS last year was $3.95. The consensus estimate for the next quarter is $4.72, with high estimates of $4.96 and low estimates of $4.32.
Analysts are recommending an EPS of between $19.75 and $18.48 for the fiscal current year, implying an average EPS of $18.95. EPS for the following year is $21.06, with 16 analysts recommending between $25.65 and $17.26.
Revenue Estimates
According to 17 analysts, the current quarter’s revenue is expected to be $956.6M. It ranges from a high estimate of $1.02B to a low estimate of $903.7M. As of the current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $892.81M, an estimated increase of 7.10% from the year-ago figure. For the next quarter, 17 analysts are estimating revenue of $1.02B, an increase of 6.70% less than the figure of $7.10% in the same quarter last year. There is a high estimate of $1.05B for the next quarter, whereas the lowest estimate is $988M.
A total of 19 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.27B, while the lowest revenue estimate was $4B, resulting in an average revenue estimate of $4.1B. In the same quarter a year ago, actual revenue was $3.83B, up 7.00% from the average estimate. Based on 19 analysts’ estimates, the company’s revenue will be $4.4B in the next fiscal year. The high estimate is $4.64B and the low estimate is $4.15B. The average revenue growth estimate for next year is up 7.20% from the average revenue estimate for this year.
